Proficio Capital Partners LLC Acquires Shares of 94,504 The Cooper Companies, Inc. (NASDAQ:COO)

Proficio Capital Partners LLC acquired a new position in The Cooper Companies, Inc. (NASDAQ:COO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 94,504 shares of the medical device company’s stock, valued at approximately $95,000.

Several other large investors also recently made changes to their positions in COO. Fulton Bank N.A. increased its stake in shares of Cooper Companies by 3.0% in the 4th quarter. Fulton Bank N.A. now owns 3,718 shares of the medical device company’s stock valued at $342,000 after buying an additional 109 shares during the period. Mather Group LLC. increased its position in Cooper Companies by 7.4% in the fourth quarter. Mather Group LLC. now owns 1,926 shares of the medical device company’s stock worth $177,000 after purchasing an additional 133 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in Cooper Companies by 15.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,008 shares of the medical device company’s stock worth $93,000 after purchasing an additional 136 shares during the last quarter. Greenleaf Trust lifted its position in Cooper Companies by 5.0% during the 4th quarter. Greenleaf Trust now owns 2,915 shares of the medical device company’s stock valued at $268,000 after purchasing an additional 139 shares during the period. Finally, UMB Bank n.a. boosted its stake in shares of Cooper Companies by 22.5% in the 4th quarter. UMB Bank n.a. now owns 773 shares of the medical device company’s stock valued at $71,000 after purchasing an additional 142 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on COO. Citigroup reduced their price objective on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Robert W. Baird reduced their price target on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Morgan Stanley dropped their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Friday, December 6th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. Finally, Stifel Nicolaus lowered their price target on Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Cooper Companies presently has an average rating of “Moderate Buy” and a consensus price target of $111.89.

Cooper Companies Price Performance

NASDAQ COO opened at $77.73 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The stock has a market cap of $15.51 billion, a price-to-earnings ratio of 39.86, a PEG ratio of 2.25 and a beta of 1.02. The business has a 50 day simple moving average of $91.67 and a 200 day simple moving average of $99.11. The Cooper Companies, Inc. has a 52-week low of $77.05 and a 52-week high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.